Vedolizumab is a gut-selective immunosuppressive biologic drug. It is a humanised monoclonal antibody integrin antagonist. It binds specifically to the alpha-4, beta-7 (α4β7) integrin, which is preferentially expressed on gut-homing T-helper lymphocytes.1
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Any adverse events observed following the prescription of Entyvio ▼ should be reported. In the United Kingdom, adverse event reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.